Sirtex Medical shares are on a tear

Photo: Jack Guez/AFP/Getty Images

Shares in Sirtex Medical jumped after the liver cancer treatment group announced a better than expected lift in earnings.

A short time ago, the shares were up 12.%% to $17.61.

The company said EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) for the six months to December is expected to be to about $34 million, up 16% growth on the same six months last year.

CEO Andrew McLean says he anticipate higher sales in the second half, resulting in full year EBITDA in the range of $75 million to $85 million. This compares to an underlying EBITDA of $61.5 million in the 2017 financial year.

Sirtex makes radioactive spheres to treat liver cancer.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at